Barclays PLC reaffirmed their overweight rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Thursday, May 11th. Barclays PLC currently has a GBX 6,000 ($77.53) price objective on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the stock. Liberum Capital reissued a buy rating and issued a GBX 5,100 ($65.90) price target on shares of AstraZeneca plc in a research report on Thursday, April 27th. Berenberg Bank dropped their price target on shares of AstraZeneca plc from GBX 5,500 ($71.07) to GBX 5,450 ($70.42) and set a buy rating on the stock in a research note on Tuesday, February 21st. Deutsche Bank AG restated a buy rating and set a GBX 5,500 ($71.07) target price on shares of AstraZeneca plc in a research report on Wednesday, March 15th. Societe Generale reiterated a buy rating on shares of AstraZeneca plc in a research report on Thursday, March 23rd. Finally, Credit Suisse Group AG reiterated an underperform rating and issued a GBX 4,000 ($51.69) price target on shares of AstraZeneca plc in a research report on Wednesday, April 19th. Six analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of GBX 5,026.80 ($64.95).
AstraZeneca plc (LON AZN) traded down 0.39% on Thursday, hitting GBX 5343.00. The stock had a trading volume of 1,637,128 shares. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The stock’s 50-day moving average is GBX 4,929.74 and its 200 day moving average is GBX 4,624.76. The firm’s market capitalization is GBX 67.64 billion.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/06/05/astrazeneca-plcs-azn-overweight-rating-reiterated-at-barclays-plc-updated-updated.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca plc? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for AstraZeneca plc and related companies.